posted on 2012-12-13, 00:00authored byKevin
L. Bicker, Lynne Anguish, Alexander A. Chumanevich, Michael D. Cameron, Xiangli Cui, Erin Witalison, Venkataraman Subramanian, Xuesen Zhang, Alena P. Chumanevich, Lorne J. Hofseth, Scott A. Coonrod, Paul R. Thompson
The protein arginine deiminases (PADs) are known to play
a crucial role in the onset and progression of multiple inflammatory
diseases, including rheumatoid arthritis, inflammatory bowel disease,
and cancer. However, it is not known how each of the five PAD isozymes
contributes to disease pathogenesis. As such, potent, selective, and
bioavailable PAD inhibitors will be useful chemical probes to elucidate
the specific roles of each isozyme. Because d-amino amino
acids often possess enhanced in cellulo stability, and perhaps unique
selectivities, we synthesized a series of d-amino acid analogues
of our pan-PAD inhibitor Cl-amidine, hypothesizing that this change
would provide inhibitors with enhanced pharmacokinetic properties.
Herein, we demonstrate that d-Cl-amidine and d-o-F-amidine are potent and highly selective inhibitors of
PAD1. The pharmacokinetic properties of d-Cl-amidine were
moderately improved over those of l-Cl-amidine, and this
compound exhibited similar cell killing in a PAD1 expressing, triple-negative
MDA-MB-231 breast cancer cell line. These inhibitors represent an
important step in our efforts to develop stable, bioavailable, and
highly selective inhibitors for all of the PAD isozymes.